Valsartan Recall Lawsuit

Nov. 6, 2018 Update:  Aurobindo Pharma Limited announced a voluntary recall of certain lots of the irbesartan, distributed by Sciegen Pharmaceuticals INC, USA, due to potential contamination with the carcinogen, N-Nitrosodiethylamine (NDEA). See recalled lots below.

Valsartan is a drug used to treat high blood pressure and heart failure. The drug is known to be highly effective at treating these conditions. However, a manufacturing issue has left many patients concerned. On July 13, 2018, the Food and Drug Administration (FDA) recalled various batches of the drug due to contamination issues. The drug is known to contain trace amounts of NDMA, which is a chemical that can cause cancer. It is believed that the NDMA contamination occurred when changes were made to the manufacturing process.

A follow-up recall on August 23, 2018 listed all the lots that could be affected by this contamination. The United States was the 23rd country to recall Valsartan. Currently, the FDA is assessing the possible effects on patients and looking for ways to ensure that NDMA is not found in future batches of Valsartan.

If you developed cancer while taking Valsartan, you may be able to recover compensation for damages. Contact Nadrich & Cohen now for a free consultation by calling (800) 718-4658. We are handling these cases nationwide.

Does Valsartan Cause Cancer?

Valsartan by itself does not cause cancer. However, it was recently discovered that worldwide, 2,300 batches of the drug were contaminated with trace amounts of NDMA.NDMA is a carcinogen that has the potential to cause certain types of cancer.

The Valsartan Recall Attorneys of Nadrich & Cohen are currently investigating cases where patients developed any of the below types of cancer after using Valsartan.

Cancer Types That We are Currently Investigating

  • Liver
  • Colorectal
  • Stomach/Gastric
  • Kidney
  • Bladder
  • Pancreatic

We are also investigating claims where the patient suffered liver failure following Valsartan use.

What is NDMA?

NDMA is the chemical compound N-nitrosodimethylamine, which is a known carcinogen. It is found naturally in drinking water and certain foods that we eat. It is also found in air pollution and industrial processes. It was once used to make rocket fuel, but now is used only for research purposes.

NDMA exposure can cause headaches, fever, nausea and vomiting. It can also affect normal function of organs such as lungs, liver and kidneys.

How Do I Know If My Valsartan Medicine Has Been Recalled?

Valsartan medication from the following manufacturers has been recalled:

  • Remedy Repack, Inc. (Torrent)
  • Teva Pharmaceuticals labeled as Major Pharmaceuticals
  • Prinston Pharmaceutical Inc. labeled as Solco Healthcare LLC
  • Teva Pharmaceuticals USA labeled as Actavis
  • AvKARE (Teva/Actavis)
  • Remedy Repack Inc. (Prinston/Solco)
  • A-S Medication Solutions LLC (Teva/Actavis & Prinston/Solco)
  • Bryant Ranch Prepack Inc. (Teva/Actavis)
  • H J Harkins Company Inc. dba Pharma Pac (Prinston/Solco)
  • Northwind Pharmaceuticals (Teva/Actavis)
  • Hetero Labs, Inc. labeled as Camber Pharmaceuticals, Inc
  • NuCare Pharmaceuticals Inc. (Prinston/Solco)
  • Remedy Repack, Inc. (Hetero/Camber)
  • AvKARE (Hetero/Camber)
  • Preferred Pharmaceuticals, Inc. (Hetero/Camber)
  • Torrent Pharmaceuticals Limited

The following batch numbers are affected:

BBX2D025 BBX2D026 BBX2E001 BBX2E002 BBX2E003
BBX2E004 BBX2E005 BBX9D004 BBX9E001 BBY1E001
BBY1E003 BBY2E001 BBY4D004 BBY4E001 BBY4E001
BBX2D003 BBX2D004 BBX2D005 BBX2D006 BBX2D007
BBX2D008 BBX2D015 BBX2D016 BBX2D017 BBX2D018
BBX2D019 BBX2D020 BBX2D021 BBX2D022 BBX2D023
BBX2D024 BBX9D001 BBY1C002 BBY1E002 BBY2D001
BBY2D002 BV53D004 BV65D002 BV77D013 BV84D010
BV84E001 BBX2D001 BBX2D002 BBX2D009 BBX2D010
BBX2D011 BBX2D012 BBX2D013 BBX2D014 BBX9D002
BBX9D003 BBY1D001 BBY4D001 BBY4D002 BBY4D003
BV46C007 BV46C008 BV46C009 BV46C010 BV46C011
BV46C012 BV47C005 BV47C006 BV47D001 BV48D001
BV48D002 BV53C006 BV53D001 BV53D002 BV53D003
BV65C002 BV65C003 BV65C004 BV65D001 BV77C011
BV77D001 BV77D002 BV77D003 BV77D004 BV77D005
BV77D006 BV77D007 BV77D008 BV77D009 BV77D010
BV77D011 BV77D012 BV84C011 BV84D001 BV84D002
BV84D005 BV84D006 BV84D007 BV84D008 BV84D009
BV77C009 BV77C010 BV53C004 BV53C005 BV84C006
BV84C007 BV84C008 BV84C009 BBX2C007 BV47C003
BV47C004 BV46C003 BV46C006
Manufacturer Batch Number Dispatch Batch Number Manufacture Date Expiry Date Customer Name
1601100782 1601101589 Jan-2016 Dec-2016 Sciegen Pharmaceuticals INC, USA
1601100783 1601101590 Jan-2016 Dec-2016 Sciegen Pharmaceuticals INC, USA
1701111861 1701113404 l3-Sep-2017 12-Sep-2020 Sciegen Pharmaceuticals INC, USA
1701112170 1701113405 l8-Sep-2017 l7-Sep-2020 Sciegen Pharmaceuticals INC, USA
1701112501 1701113406 20-Sep-2017 l9-Sep-2020 Sciegen Pharmaceuticals INC, USA
1701112056 1701113407 l3-Sep-2017 l2-Sep-2020 Sciegen Pharmaceuticals INC, USA
1701112558 1701114283 2-0ct-2017 l-Oct-2020 Sciegen Pharmaceuticals INC, USA
1701112558 1701114284 2-0ct-2017 l-Oct-2020 Sciegen Pharmaceuticals INC, USA
1701I12559 1701114285 3-0ct-2017 2-0ct-2020 Sciegen Pharmaceuticals INC, USA
1701112589 1701114286 6-0ct-2017 5-0ct-2020 Sciegen Pharmaceuticals INC, USA
1701113300 1701114289 7-0ct-2017 6-0ct-2020 Sciegen Pharmaceuticals INC, USA
1701113301 1701114291 8-0ct-2017 7-0ct-2020 Sciegen Pharmaceuticals INC, USA
1701113302 1701114708 l7-0ct-2017 l6-0ct-2020 Sciegen Pharmaceuticals INC, USA
1701113312 1701114709 20-0ct-2017 19 Oct 2020 Sciegen Pharmaceuticals INC, USA
1701115460 1701117039 23-Nov-2017 22-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115974 1701117040 29-Nov-2017 28-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115460 1701117041 23-Nov-2017 22-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115738 1701117042 24-Nov-2017 23-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115739 1701117043 25-Nov-2017 24-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115740 1701117044 26-Nov-2017 25-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115741 1701117045 27-Nov-2017 26-Nov-2020 Sciegen Pharmaceuticals INC, USA
1701115742 1701117046 28-Nov-2017 27-Nov-2020 Sciegen Pharmaceuticals INC, USA

If your drug is on this list, do not stop taking Valsartan until you consult with your prescribing doctor. Abrupt cessation of the drug can lead to a heart attack, stroke or heart failure. Consult with your doctor, who can advise you of the next steps. You may be able to switch to a different Valsartan product which has not been associated with NDMA contamination.

Do I Have A Case?

If you or a loved one developed one of the above cancer types or suffered liver failure after taking Valsartan, you may be able to recover compensation for your injuries. Contact the Valsartan Recall Lawyers of Nadrich & Cohen now for a free consultation by calling (800) 718-4658. We are handling these cases nationwide.